Fuzuloparib
PARP trapper; approved in China for BRCA-mutated recurrent ovarian cancer 2021. First China-approved PARPi; maintenance indication
Description
Scientific Overview: PARP trapper; approved in China for BRCA-mutated recurrent ovarian cancer 2021. First China-approved PARPi; maintenance indication
Mechanism of Action: PARP1/2 Inhibitor
Purity: ≥99% | Molecular Formula: C20H19FN4O3
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | PARP1/2 Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C20H19FN4O3 |
| CAS Number | 1802075-31-5 |
